{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-002907","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.775452+00:00","generated_at":"2026-05-28T08:50:19.628106+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025","bullets":["Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.","Full-year 2024 revenue now ~$64.3M (29% YoY growth) vs prior $68-70M.","FY 2025 revenue guidance $100-106M (55-65% growth).","Cashflow breakeven and GAAP profitability now expected in Q4 2025, delayed from Q3 2025.","Miss attributed to slower hospital year-end purchasing; new products RECELL GO and Cohealyx remain growth drivers."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-002907","json":"https://secwatch.observer/filing/0000950170-25-002907.json","markdown":"https://secwatch.observer/filing/0000950170-25-002907.md","text":"https://secwatch.observer/filing/0000950170-25-002907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017025002907/0000950170-25-002907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017025002907/rcel-20250107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:50:19.628106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}